Fusion Pharmaceuticals Inc Quick Ratio (FUSN) starting from the first quarter 2024 to first quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Fusion Pharmaceuticals Inc   (NASDAQ: FUSN)

Fusion Pharmaceuticals Inc 's Quick Ratio

FUSN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2024, Quick Ratio fell to 12.78 below Fusion Pharmaceuticals Inc average.

Within Biotechnology & Pharmaceuticals industry 31 other companies have achieved higher Quick Ratio than Fusion Pharmaceuticals Inc in first quarter 2024. While Quick Ratio total ranking in the first quarter 2024 has deteriorated compared to the prior quarter from 156 to 272.

Explain Quick Ratio?
How much Cash & cash equivalents FUSN´s has?
What are FUSN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FUSN Quick Ratio (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1
Y / Y Current Liabilities Change 29.8 % -11.5 % -5.58 % 15.76 % 18.04 %
Y / Y Cash & cash equivalent Change 0.32 % 36.71 % -6.88 % -0.16 % 6.62 %
Quick Ratio MRQ 12.78 19.38 16.92 16.88 16.54
FUSN's Total Ranking # 272 # 156 # 187 # 201 # 160
Seq. Current Liabilities Change 36.58 % 6.59 % -3.62 % -7.49 % -6.88 %
Seq. Cash & cash equivalent Change -9.88 % 22.09 % -3.41 % -5.6 % 22.81 %



Quick Ratio first quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 32
Healthcare Sector # 129
Overall Market # 272


Quick Ratio Statistics
High Average Low
54.99 22.05 12.54
(Sep 30 2020)   (Dec 31 2022)




Financial Statements
Fusion Pharmaceuticals Inc 's Current Liabilities $ 16 Millions Visit FUSN's Balance sheet
Fusion Pharmaceuticals Inc 's Cash & cash equivalent $ 211 Millions Visit FUSN's Balance sheet
Source of FUSN's Sales Visit FUSN's Sales by Geography


Cumulative Fusion Pharmaceuticals Inc 's Quick Ratio

FUSN's Quick Ratio for the trailling 12 Months

FUSN Quick Ratio

 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months
Y / Y Current Liabilities TTM Growth 6.49 % 2.8 % 23.7 % 24.58 % 27.06 %
Y / Y Cash & cash equivalent TTM Growth 6.24 % 7.95 % -3.91 % -0.55 % 2.07 %
Quick Ratio TTM 16.16 17.43 15.6 15.68 16.2
Total Ranking TTM # 2978 # 2874 # 25 # 2948 # 3078
Seq. Current Liabilities TTM Growth 7.91 % -3.17 % -1.34 % 3.3 % 4.17 %
Seq. Cash & cash equivalent TTM Growth 0.08 % 8.15 % -1.8 % -0.04 % 1.69 %

Quick ratio ranking by company, industry and sector >> Back to FUSN Financial Strength Comparisons >> Go to Compare FUSN Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q1 2024 to $16.47 millions, cumulative Quick Ratio decreased to 16.16 below the Fusion Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 148 other companies have achieved higher Quick Ratio than Fusion Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2023 from 2874 to 2978.

Explain Quick Ratio?
How much Cash & cash equivalents FUSN´s has?
What are FUSN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 149
Healthcare Sector # 911
Within the Market # 2978


trailing twelve months Quick Ratio Statistics
High Average Low
32.74 17.35 11.5
(Mar 31 2021)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Mar 31 2024, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2024 MRQ Cash & cash equivalentMar 31 2024 MRQ Current Liabilities
4d Molecular Therapeutics Inc   32.06 $ 525.911  Millions$ 16.403  Millions
Acumen Pharmaceuticals Inc   29.81 $ 252.512  Millions$ 8.472  Millions
Protara Therapeutics Inc  23.77 $ 107.004  Millions$ 4.501  Millions
Kymera Therapeutics Inc   22.03 $ 520.544  Millions$ 23.633  Millions
Cullinan Therapeutics Inc   21.02 $ 433.011  Millions$ 20.596  Millions
Aura Biosciences Inc   20.99 $ 202.874  Millions$ 9.663  Millions
Autolus Therapeutics Plc  19.37 $ 758.529  Millions$ 39.167  Millions
Voyager Therapeutics Inc   18.92 $ 399.568  Millions$ 21.114  Millions
Vaxcyte Inc   18.82 $ 1,486.518  Millions$ 78.976  Millions
Prokidney Corp   18.07 $ 328.998  Millions$ 18.209  Millions
Crispr Therapeutics Ag  17.72 $ 2,108.125  Millions$ 118.990  Millions
Neumora Therapeutics Inc   17.18 $ 422.715  Millions$ 24.609  Millions
Kyverna Therapeutics Inc   16.91 $ 369.794  Millions$ 21.865  Millions
Cargo Therapeutics Inc   16.60 $ 375.913  Millions$ 22.649  Millions
Anavex Life Sciences Corp   16.13 $ 139.386  Millions$ 8.641  Millions
Tradeup Acquisition Corp  15.91 $ 4.727  Millions$ 0.297  Millions
Imagenebio Inc   15.47 $ 157.349  Millions$ 10.169  Millions
In8bio Inc   14.54 $ 13.015  Millions$ 0.895  Millions
Solid Biosciences Inc   14.37 $ 206.066  Millions$ 14.339  Millions
Jasper Therapeutics Inc   13.29 $ 118.475  Millions$ 8.916  Millions
Immunovant Inc   13.11 $ 635.365  Millions$ 48.470  Millions
Fusion Pharmaceuticals Inc   12.78 $ 210.525  Millions$ 16.468  Millions
Allogene Therapeutics Inc   12.46 $ 384.860  Millions$ 30.894  Millions
Cabaletta Bio Inc   12.46 $ 223.845  Millions$ 17.972  Millions
Vir Biotechnology Inc   12.32 $ 1,159.171  Millions$ 94.068  Millions
Century Therapeutics inc   11.95 $ 192.016  Millions$ 16.065  Millions
Vigil Neuroscience Inc   11.82 $ 101.645  Millions$ 8.603  Millions
Vor Biopharma Inc   11.61 $ 107.479  Millions$ 9.256  Millions
Denali Therapeutics Inc   11.34 $ 936.869  Millions$ 82.582  Millions
Krystal Biotech Inc   11.31 $ 538.259  Millions$ 47.589  Millions

Date modified: 2026-09-08T15:22:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.